Society guideline links: Cutaneous graft-versus-host disease

Introduction — This topic includes links to society and government-sponsored guidelines from selected countries and regions around the world. We will update these links periodically; newer versions of some guidelines may be available on each society's website. Some societies may require users to log in to access their guidelines.

The recommendations in the following guidelines may vary from those that appear in UpToDate topic reviews. Readers who are looking for UpToDate topic reviews should use the UpToDate search box to find the relevant content.

Canada

●Choosing Wisely Canada: Don't use greater than 2 mg/kg/day of methylprednisolone (or equivalent) for the initial treatment of graft-versus-host disease (updated 2020)

Europe

●European Dermatology Forum (EDF): European guidelines (S1) on the use of extracorporeal photopheresis, update (2020)

●European Academy of Dermatology and Venerology (EADV): Guidelines on the use of extracorporeal photopheresis (2014)

United Kingdom

●UK Photopheresis Society: Consensus statement update on the role of extracorporeal photophoresis in the management of cutaneous T-cell lymphoma, graft-versus-host disease and organ transplant rejection (2017)

●U.K. consensus statement on the use of extracorporeal photopheresis for treatment of cutaneous T-cell lymphoma and chronic graft-versus-host disease (2008)